AU746163B2 - Adjuvant compositions - Google Patents

Adjuvant compositions Download PDF

Info

Publication number: AU746163B2
Authority: AU; Australia
Prior art keywords: polyoxyethylene; vaccine; vaccine composition; alkyl; surfactant
Prior art date: 1998-04-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

AU34197/99A

Other languages

English (en)

Other versions

AU3419799A (en

Inventor

Martin Friede

Philippe Hermand

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

GlaxoSmithKline Biologicals SA

Original Assignee

SmithKline Beecham Biologicals SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-04-09

Filing date

1999-03-29

Publication date

2002-04-18

1998-04-09 Priority claimed from GBGB9807805.8A external-priority patent/GB9807805D0/en

1998-09-25 Priority claimed from GBGB9820956.2A external-priority patent/GB9820956D0/en

1999-03-29 Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA

1999-11-01 Publication of AU3419799A publication Critical patent/AU3419799A/en

2002-04-18 Application granted granted Critical

2002-04-18 Publication of AU746163B2 publication Critical patent/AU746163B2/en

2019-03-29 Anticipated expiration legal-status Critical

Status Ceased legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims description 82
239000002671 adjuvant Substances 0.000 title claims description 66
239000000427 antigen Substances 0.000 claims description 94
102000036639 antigens Human genes 0.000 claims description 94
108091007433 antigens Proteins 0.000 claims description 94
229960005486 vaccine Drugs 0.000 claims description 89
CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 claims description 44
229920000056 polyoxyethylene ether Polymers 0.000 claims description 36
239000004094 surface-active agent Substances 0.000 claims description 27
150000002148 esters Chemical class 0.000 claims description 25
125000000217 alkyl group Chemical group 0.000 claims description 20
241000701806 Human papillomavirus Species 0.000 claims description 17
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 14
241000700605 Viruses Species 0.000 claims description 13
206010028980 Neoplasm Diseases 0.000 claims description 12
239000000243 solution Substances 0.000 claims description 12
230000003308 immunostimulating effect Effects 0.000 claims description 11
238000000034 method Methods 0.000 claims description 11
239000000546 pharmaceutical excipient Substances 0.000 claims description 11
230000000890 antigenic effect Effects 0.000 claims description 10
238000004519 manufacturing process Methods 0.000 claims description 10
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
239000000725 suspension Substances 0.000 claims description 9
229960001438 immunostimulant agent Drugs 0.000 claims description 8
239000003022 immunostimulating agent Substances 0.000 claims description 8
238000003556 assay Methods 0.000 claims description 7
230000002949 hemolytic effect Effects 0.000 claims description 7
229940051841 polyoxyethylene ether Drugs 0.000 claims description 7
108090000765 processed proteins & peptides Proteins 0.000 claims description 7
241000712461 unidentified influenza virus Species 0.000 claims description 7
241000124008 Mammalia Species 0.000 claims description 6
210000004369 blood Anatomy 0.000 claims description 6
239000008280 blood Substances 0.000 claims description 6
208000015181 infectious disease Diseases 0.000 claims description 6
231100000252 nontoxic Toxicity 0.000 claims description 6
230000003000 nontoxic effect Effects 0.000 claims description 6
102000004196 processed proteins & peptides Human genes 0.000 claims description 6
239000007921 spray Substances 0.000 claims description 6
HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 claims description 5
206010018910 Haemolysis Diseases 0.000 claims description 5
230000008588 hemolysis Effects 0.000 claims description 5
229940035032 monophosphoryl lipid a Drugs 0.000 claims description 5
208000002672 hepatitis B Diseases 0.000 claims description 4
238000012737 microarray-based gene expression Methods 0.000 claims description 4
238000012243 multiplex automated genomic engineering Methods 0.000 claims description 4
229930182490 saponin Natural products 0.000 claims description 4
150000007949 saponins Chemical class 0.000 claims description 4
125000006539 C12 alkyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
206010020751 Hypersensitivity Diseases 0.000 claims description 3
241000588653 Neisseria Species 0.000 claims description 3
241000224016 Plasmodium Species 0.000 claims description 3
208000026935 allergic disease Diseases 0.000 claims description 3
230000007815 allergy Effects 0.000 claims description 3
201000011510 cancer Diseases 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
230000001717 pathogenic effect Effects 0.000 claims description 3
239000001397 quillaja saponaria molina bark Substances 0.000 claims description 3
102100035526 B melanoma antigen 1 Human genes 0.000 claims description 2
241000588807 Bordetella Species 0.000 claims description 2
241000589968 Borrelia Species 0.000 claims description 2
101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 claims description 2
241000606161 Chlamydia Species 0.000 claims description 2
241000725619 Dengue virus Species 0.000 claims description 2
241000606790 Haemophilus Species 0.000 claims description 2
101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 claims description 2
241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 2
241000701074 Human alphaherpesvirus 2 Species 0.000 claims description 2
241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 2
208000016604 Lyme disease Diseases 0.000 claims description 2
108010008707 Mucin-1 Proteins 0.000 claims description 2
102100034256 Mucin-1 Human genes 0.000 claims description 2
102000036673 PRAME Human genes 0.000 claims description 2
108060006580 PRAME Proteins 0.000 claims description 2
241000607142 Salmonella Species 0.000 claims description 2
241000194017 Streptococcus Species 0.000 claims description 2
241000223996 Toxoplasma Species 0.000 claims description 2
239000000693 micelle Substances 0.000 claims description 2
241000700199 Cavia porcellus Species 0.000 claims 2
208000005176 Hepatitis C Diseases 0.000 claims 1
241000701024 Human betaherpesvirus 5 Species 0.000 claims 1
201000009906 Meningitis Diseases 0.000 claims 1
241000204031 Mycoplasma Species 0.000 claims 1
239000000443 aerosol Substances 0.000 claims 1
239000007864 aqueous solution Substances 0.000 claims 1
229960000074 biopharmaceutical Drugs 0.000 claims 1
208000005252 hepatitis A Diseases 0.000 claims 1
201000010284 hepatitis E Diseases 0.000 claims 1
208000013292 immunodeficiency 20 Diseases 0.000 claims 1
230000000241 respiratory effect Effects 0.000 claims 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 33
238000009472 formulation Methods 0.000 description 33
239000002953 phosphate buffered saline Substances 0.000 description 33
108700006640 OspA Proteins 0.000 description 32
230000028993 immune response Effects 0.000 description 29
241000699670 Mus sp. Species 0.000 description 24
230000004044 response Effects 0.000 description 24
230000009885 systemic effect Effects 0.000 description 23
210000002966 serum Anatomy 0.000 description 21
239000000872 buffer Substances 0.000 description 20
-1 polyoxyethylene Polymers 0.000 description 20
229920001213 Polysorbate 20 Polymers 0.000 description 19
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 19
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 19
238000002255 vaccination Methods 0.000 description 18
235000018102 proteins Nutrition 0.000 description 16
102000004169 proteins and genes Human genes 0.000 description 16
108090000623 proteins and genes Proteins 0.000 description 16
229920003171 Poly (ethylene oxide) Polymers 0.000 description 15
238000010790 dilution Methods 0.000 description 13
239000012895 dilution Substances 0.000 description 13
239000007924 injection Substances 0.000 description 13
238000002347 injection Methods 0.000 description 13
241001465754 Metazoa Species 0.000 description 12
230000000694 effects Effects 0.000 description 12
238000002965 ELISA Methods 0.000 description 11
102000037865 fusion proteins Human genes 0.000 description 10
108020001507 fusion proteins Proteins 0.000 description 10
241000282552 Chlorocebus aethiops Species 0.000 description 9
108060003951 Immunoglobulin Proteins 0.000 description 9
102000018358 immunoglobulin Human genes 0.000 description 9
206010022000 influenza Diseases 0.000 description 9
239000002245 particle Substances 0.000 description 9
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
150000004676 glycans Chemical class 0.000 description 8
229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 8
229920001282 polysaccharide Polymers 0.000 description 8
239000005017 polysaccharide Substances 0.000 description 8
238000002360 preparation method Methods 0.000 description 8
239000003053 toxin Substances 0.000 description 8
231100000765 toxin Toxicity 0.000 description 8
108700012359 toxins Proteins 0.000 description 8
102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 description 7
101710188053 Protein D Proteins 0.000 description 7
101710132893 Resolvase Proteins 0.000 description 7
238000010255 intramuscular injection Methods 0.000 description 7
239000007927 intramuscular injection Substances 0.000 description 7
230000003389 potentiating effect Effects 0.000 description 7
230000037452 priming Effects 0.000 description 7
241000283707 Capra Species 0.000 description 6
241000588724 Escherichia coli Species 0.000 description 6
101710082439 Hemagglutinin A Proteins 0.000 description 6
108091034117 Oligonucleotide Proteins 0.000 description 6
230000000240 adjuvant effect Effects 0.000 description 6
230000003287 optical effect Effects 0.000 description 6
206010002091 Anaesthesia Diseases 0.000 description 5
241000282693 Cercopithecidae Species 0.000 description 5
108010049048 Cholera Toxin Proteins 0.000 description 5
102000009016 Cholera Toxin Human genes 0.000 description 5
229940037003 alum Drugs 0.000 description 5
230000037005 anaesthesia Effects 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
230000006698 induction Effects 0.000 description 5
238000012067 mathematical method Methods 0.000 description 5
238000005259 measurement Methods 0.000 description 5
229920000136 polysorbate Polymers 0.000 description 5
239000011534 wash buffer Substances 0.000 description 5
238000005406 washing Methods 0.000 description 5
PMTMAFAPLCGXGK-JMTMCXQRSA-N (15Z)-12-oxophyto-10,15-dienoic acid Chemical compound CC\C=C/C[C@H]1[C@@H](CCCCCCCC(O)=O)C=CC1=O PMTMAFAPLCGXGK-JMTMCXQRSA-N 0.000 description 4
PMTMAFAPLCGXGK-UHFFFAOYSA-N OPDA Natural products CCC=CCC1C(CCCCCCCC(O)=O)C=CC1=O PMTMAFAPLCGXGK-UHFFFAOYSA-N 0.000 description 4
101100028078 Oryza sativa subsp. japonica OPR1 gene Proteins 0.000 description 4
108700023315 OspC Proteins 0.000 description 4
101100431670 Rattus norvegicus Ybx3 gene Proteins 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
235000012000 cholesterol Nutrition 0.000 description 4
239000007979 citrate buffer Substances 0.000 description 4
239000003599 detergent Substances 0.000 description 4
238000002649 immunization Methods 0.000 description 4
238000007918 intramuscular administration Methods 0.000 description 4
239000012528 membrane Substances 0.000 description 4
210000004379 membrane Anatomy 0.000 description 4
239000002736 nonionic surfactant Substances 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
102000003992 Peroxidases Human genes 0.000 description 3
208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
235000001014 amino acid Nutrition 0.000 description 3
150000001413 amino acids Chemical group 0.000 description 3
229960001212 bacterial vaccine Drugs 0.000 description 3
239000000147 enterotoxin Substances 0.000 description 3
231100000655 enterotoxin Toxicity 0.000 description 3
230000004927 fusion Effects 0.000 description 3
230000036039 immunity Effects 0.000 description 3
201000001441 melanoma Diseases 0.000 description 3
244000052769 pathogen Species 0.000 description 3
108040007629 peroxidase activity proteins Proteins 0.000 description 3
125000003884 phenylalkyl group Chemical group 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
238000011282 treatment Methods 0.000 description 3
239000012646 vaccine adjuvant Substances 0.000 description 3
229940124931 vaccine adjuvant Drugs 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
206010059313 Anogenital warts Diseases 0.000 description 2
108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
241000193403 Clostridium Species 0.000 description 2
208000000907 Condylomata Acuminata Diseases 0.000 description 2
101710146739 Enterotoxin Proteins 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 2
241000606768 Haemophilus influenzae Species 0.000 description 2
241000700721 Hepatitis B virus Species 0.000 description 2
241000282412 Homo Species 0.000 description 2
241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
241000701828 Human papillomavirus type 11 Species 0.000 description 2
108090001030 Lipoproteins Proteins 0.000 description 2
102000004895 Lipoproteins Human genes 0.000 description 2
101710105759 Major outer membrane porin Proteins 0.000 description 2
101710164702 Major outer membrane protein Proteins 0.000 description 2
101710085938 Matrix protein Proteins 0.000 description 2
101710127721 Membrane protein Proteins 0.000 description 2
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
241000223960 Plasmodium falciparum Species 0.000 description 2
102100035181 Plastin-1 Human genes 0.000 description 2
229920001214 Polysorbate 60 Polymers 0.000 description 2
241000288906 Primates Species 0.000 description 2
102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 2
238000013019 agitation Methods 0.000 description 2
239000013566 allergen Substances 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 2
239000012888 bovine serum Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000004359 castor oil Substances 0.000 description 2
235000019438 castor oil Nutrition 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
NLEBIOOXCVAHBD-QKMCSOCLSA-N dodecyl beta-D-maltoside Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLEBIOOXCVAHBD-QKMCSOCLSA-N 0.000 description 2
238000005538 encapsulation Methods 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
102000022382 heparin binding proteins Human genes 0.000 description 2
108091012216 heparin binding proteins Proteins 0.000 description 2
230000028996 humoral immune response Effects 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
239000002502 liposome Substances 0.000 description 2
229940124735 malaria vaccine Drugs 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
244000045947 parasite Species 0.000 description 2
108010049148 plastin Proteins 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
230000002797 proteolythic effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
235000017709 saponins Nutrition 0.000 description 2
230000028327 secretion Effects 0.000 description 2
241000894007 species Species 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
206010001935 American trypanosomiasis Diseases 0.000 description 1
101100162403 Arabidopsis thaliana ALEU gene Proteins 0.000 description 1
240000005528 Arctium lappa Species 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
241000223836 Babesia Species 0.000 description 1
241000193830 Bacillus <bacterium> Species 0.000 description 1
241000193738 Bacillus anthracis Species 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
206010005003 Bladder cancer Diseases 0.000 description 1
108030001720 Bontoxilysin Proteins 0.000 description 1
241000588780 Bordetella parapertussis Species 0.000 description 1
241000588832 Bordetella pertussis Species 0.000 description 1
241000589978 Borrelia hermsii Species 0.000 description 1
241000495356 Borrelia microti Species 0.000 description 1
241000589972 Borrelia sp. Species 0.000 description 1
241001148604 Borreliella afzelii Species 0.000 description 1
241000142472 Borreliella andersonii Species 0.000 description 1
241000589969 Borreliella burgdorferi Species 0.000 description 1
241001148605 Borreliella garinii Species 0.000 description 1
241000589893 Brachyspira hyodysenteriae Species 0.000 description 1
241000589876 Campylobacter Species 0.000 description 1
241000222120 Candida <Saccharomycetales> Species 0.000 description 1
102000016938 Catalase Human genes 0.000 description 1
108010053835 Catalase Proteins 0.000 description 1
241000700198 Cavia Species 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
229920001661 Chitosan Polymers 0.000 description 1
241001647372 Chlamydia pneumoniae Species 0.000 description 1
241000606153 Chlamydia trachomatis Species 0.000 description 1
206010008631 Cholera Diseases 0.000 description 1
241000193155 Clostridium botulinum Species 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
241000186216 Corynebacterium Species 0.000 description 1
108091029430 CpG site Proteins 0.000 description 1
241001337994 Cryptococcus <scale insect> Species 0.000 description 1
241000221204 Cryptococcus neoformans Species 0.000 description 1
102100035353 Cyclin-dependent kinase 2-associated protein 1 Human genes 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
102100031262 Deleted in malignant brain tumors 1 protein Human genes 0.000 description 1
108010053187 Diphtheria Toxin Proteins 0.000 description 1
102000016607 Diphtheria Toxin Human genes 0.000 description 1
241000605314 Ehrlichia Species 0.000 description 1
241000224431 Entamoeba Species 0.000 description 1
241001133638 Entamoeba equi Species 0.000 description 1
241000224432 Entamoeba histolytica Species 0.000 description 1
241000194033 Enterococcus Species 0.000 description 1
241000194032 Enterococcus faecalis Species 0.000 description 1
241000194031 Enterococcus faecium Species 0.000 description 1
241000588722 Escherichia Species 0.000 description 1
108091006027 G proteins Proteins 0.000 description 1
102000030782 GTP binding Human genes 0.000 description 1
108091000058 GTP-Binding Proteins 0.000 description 1
241000224466 Giardia Species 0.000 description 1
241000224467 Giardia intestinalis Species 0.000 description 1
101100406392 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) omp26 gene Proteins 0.000 description 1
241000589989 Helicobacter Species 0.000 description 1
101710154606 Hemagglutinin Proteins 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
241000711549 Hepacivirus C Species 0.000 description 1
241000724675 Hepatitis E virus Species 0.000 description 1
241000709721 Hepatovirus A Species 0.000 description 1
101000844721 Homo sapiens Deleted in malignant brain tumors 1 protein Proteins 0.000 description 1
101001130441 Homo sapiens Ras-related protein Rap-2a Proteins 0.000 description 1
206010071038 Human anaplasmosis Diseases 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
241000710842 Japanese encephalitis virus Species 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
102100032241 Lactotransferrin Human genes 0.000 description 1
241000589248 Legionella Species 0.000 description 1
241000589242 Legionella pneumophila Species 0.000 description 1
208000007764 Legionnaires' Disease Diseases 0.000 description 1
241000589902 Leptospira Species 0.000 description 1
241000589929 Leptospira interrogans Species 0.000 description 1
239000000232 Lipid Bilayer Substances 0.000 description 1
241000186781 Listeria Species 0.000 description 1
241000186779 Listeria monocytogenes Species 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
241000712079 Measles morbillivirus Species 0.000 description 1
241001092142 Molina Species 0.000 description 1
241000588621 Moraxella Species 0.000 description 1
241000588622 Moraxella bovis Species 0.000 description 1
241000588655 Moraxella catarrhalis Species 0.000 description 1
241000711386 Mumps virus Species 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000186359 Mycobacterium Species 0.000 description 1
241000187482 Mycobacterium avium subsp. paratuberculosis Species 0.000 description 1
241000186362 Mycobacterium leprae Species 0.000 description 1
241000588652 Neisseria gonorrhoeae Species 0.000 description 1
241000588650 Neisseria meningitidis Species 0.000 description 1
HCUVEUVIUAJXRB-UHFFFAOYSA-N OC1=C(C=C(CNC(CCCC=2SC=CC=2)=O)C=C1)OC Chemical compound OC1=C(C=C(CNC(CCCC=2SC=CC=2)=O)C=C1)OC HCUVEUVIUAJXRB-UHFFFAOYSA-N 0.000 description 1
101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
101710116435 Outer membrane protein Proteins 0.000 description 1
208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
108010081690 Pertussis Toxin Proteins 0.000 description 1
101710099976 Photosystem I P700 chlorophyll a apoprotein A1 Proteins 0.000 description 1
206010035500 Plasmodium falciparum infection Diseases 0.000 description 1
241000233870 Pneumocystis Species 0.000 description 1
101710183389 Pneumolysin Proteins 0.000 description 1
239000004365 Protease Substances 0.000 description 1
101710176177 Protein A56 Proteins 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
241001454523 Quillaja saponaria Species 0.000 description 1
235000009001 Quillaja saponaria Nutrition 0.000 description 1
102100022851 Rab5 GDP/GTP exchange factor Human genes 0.000 description 1
102100031420 Ras-related protein Rap-2a Human genes 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
101710203837 Replication-associated protein Proteins 0.000 description 1
241000725643 Respiratory syncytial virus Species 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
241000606701 Rickettsia Species 0.000 description 1
241000606695 Rickettsia rickettsii Species 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
241000702670 Rotavirus Species 0.000 description 1
101000999689 Saimiriine herpesvirus 2 (strain 11) Transcriptional regulator ICP22 homolog Proteins 0.000 description 1
241001138501 Salmonella enterica Species 0.000 description 1
241000531795 Salmonella enterica subsp. enterica serovar Paratyphi A Species 0.000 description 1
241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
241000607768 Shigella Species 0.000 description 1
241000607764 Shigella dysenteriae Species 0.000 description 1
241000607760 Shigella sonnei Species 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
241000589970 Spirochaetales Species 0.000 description 1
241000191940 Staphylococcus Species 0.000 description 1
241000191963 Staphylococcus epidermidis Species 0.000 description 1
241000193985 Streptococcus agalactiae Species 0.000 description 1
241000194019 Streptococcus mutans Species 0.000 description 1
241000193996 Streptococcus pyogenes Species 0.000 description 1
108010011834 Streptolysins Proteins 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
101710137302 Surface antigen S Proteins 0.000 description 1
WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
206010043376 Tetanus Diseases 0.000 description 1
108010055044 Tetanus Toxin Proteins 0.000 description 1
208000003217 Tetany Diseases 0.000 description 1
241000710771 Tick-borne encephalitis virus Species 0.000 description 1
241000223997 Toxoplasma gondii Species 0.000 description 1
101710134694 Transcriptional regulator ICP22 homolog Proteins 0.000 description 1
102000010912 Transferrin-Binding Proteins Human genes 0.000 description 1
108010062476 Transferrin-Binding Proteins Proteins 0.000 description 1
241000589886 Treponema Species 0.000 description 1
241000589884 Treponema pallidum Species 0.000 description 1
241000224526 Trichomonas Species 0.000 description 1
241000224527 Trichomonas vaginalis Species 0.000 description 1
241000223104 Trypanosoma Species 0.000 description 1
241000223109 Trypanosoma cruzi Species 0.000 description 1
108010046334 Urease Proteins 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
241000607598 Vibrio Species 0.000 description 1
241000607626 Vibrio cholerae Species 0.000 description 1
241000710772 Yellow fever virus Species 0.000 description 1
241000607734 Yersinia <bacteria> Species 0.000 description 1
208000025087 Yersinia pseudotuberculosis infectious disease Diseases 0.000 description 1
UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
241000606834 [Haemophilus] ducreyi Species 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000000654 additive Substances 0.000 description 1
102000030621 adenylate cyclase Human genes 0.000 description 1
108060000200 adenylate cyclase Proteins 0.000 description 1
230000002411 adverse Effects 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
101150078331 ama-1 gene Proteins 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
208000025009 anogenital human papillomavirus infection Diseases 0.000 description 1
201000004201 anogenital venereal wart Diseases 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000001139 anti-pruritic effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
239000003908 antipruritic agent Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
201000008680 babesiosis Diseases 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
201000001531 bladder carcinoma Diseases 0.000 description 1
208000034158 bleeding Diseases 0.000 description 1
231100000319 bleeding Toxicity 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
229940053031 botulinum toxin Drugs 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
108091016312 choline binding proteins Proteins 0.000 description 1
229940001442 combination vaccine Drugs 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
235000013601 eggs Nutrition 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000000369 enteropathogenic effect Effects 0.000 description 1
231100000249 enterotoxic Toxicity 0.000 description 1
230000002242 enterotoxic effect Effects 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
ZINJLDJMHCUBIP-UHFFFAOYSA-N ethametsulfuron-methyl Chemical compound CCOC1=NC(NC)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)C(=O)OC)=N1 ZINJLDJMHCUBIP-UHFFFAOYSA-N 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
239000008187 granular material Substances 0.000 description 1
239000000185 hemagglutinin Substances 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
201000009163 human granulocytic anaplasmosis Diseases 0.000 description 1
208000022340 human granulocytic ehrlichiosis Diseases 0.000 description 1
244000052637 human pathogen Species 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
230000002130 immunocastration Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
230000002480 immunoprotective effect Effects 0.000 description 1
230000001024 immunotherapeutic effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
229960003971 influenza vaccine Drugs 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
230000007794 irritation Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
201000005296 lung carcinoma Diseases 0.000 description 1
201000003866 lung sarcoma Diseases 0.000 description 1
101710130522 mRNA export factor Proteins 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
239000000178 monomer Substances 0.000 description 1
229940126619 mouse monoclonal antibody Drugs 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
210000003928 nasal cavity Anatomy 0.000 description 1
239000007923 nasal drop Substances 0.000 description 1
210000002850 nasal mucosa Anatomy 0.000 description 1
239000013642 negative control Substances 0.000 description 1
239000003921 oil Substances 0.000 description 1
229940099789 ospa protein Drugs 0.000 description 1
229940047091 other immunostimulants in atc Drugs 0.000 description 1
230000036407 pain Effects 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
239000000813 peptide hormone Substances 0.000 description 1
108010021711 pertactin Proteins 0.000 description 1
229940066827 pertussis vaccine Drugs 0.000 description 1
201000000317 pneumocystosis Diseases 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
229920002851 polycationic polymer Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
229960000380 propiolactone Drugs 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
239000006215 rectal suppository Substances 0.000 description 1
239000003488 releasing hormone Substances 0.000 description 1
102200108206 rs756233241 Human genes 0.000 description 1
239000003229 sclerosing agent Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
229940118376 tetanus toxin Drugs 0.000 description 1
229960000814 tetanus toxoid Drugs 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229940021747 therapeutic vaccine Drugs 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
208000010570 urinary bladder carcinoma Diseases 0.000 description 1
230000002477 vacuolizing effect Effects 0.000 description 1
239000000522 vaginal cream Substances 0.000 description 1
239000006216 vaginal suppository Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
210000003501 vero cell Anatomy 0.000 description 1
229940118696 vibrio cholerae Drugs 0.000 description 1
244000052613 viral pathogen Species 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000000277 virosome Substances 0.000 description 1
239000001993 wax Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Microbiology (AREA)
Virology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pulmonology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)

AU34197/99A 1998-04-09 1999-03-29 Adjuvant compositions Ceased AU746163B2 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
GBGB9807805.8A GB9807805D0 (en)	1998-04-09	1998-04-09	Vaccine
GB9807805		1998-04-09
GBGB9820956.2A GB9820956D0 (en)	1998-09-25	1998-09-25	Vaccine
GB9820956		1998-09-25
PCT/EP1999/002278 WO1999052549A1 (en)	1998-04-09	1999-03-29	Adjuvant compositions

Publications (2)

Publication Number	Publication Date
AU3419799A AU3419799A (en)	1999-11-01
AU746163B2 true AU746163B2 (en)	2002-04-18

Family

ID=26313462

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU34197/99A Ceased AU746163B2 (en)	1998-04-09	1999-03-29	Adjuvant compositions

Country Status (15)

Country	Link
EP (1)	EP1069910A1 (es)
JP (1)	JP2002511423A (es)
KR (1)	KR20010042573A (es)
CN (1)	CN1296416A (es)
AR (1)	AR019026A1 (es)
AU (1)	AU746163B2 (es)
BR (1)	BR9909915A (es)
CA (1)	CA2325939A1 (es)
HU (1)	HUP0101619A3 (es)
IL (1)	IL138000A0 (es)
NO (1)	NO20005051L (es)
NZ (1)	NZ506603A (es)
PL (1)	PL354714A1 (es)
TR (1)	TR200002930T2 (es)
WO (1)	WO1999052549A1 (es)

Families Citing this family (242)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6239116B1 (en)	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US7935675B1 (en)	1994-07-15	2011-05-03	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
EP0909323B1 (en)	1996-01-04	2007-02-28	Novartis Vaccines and Diagnostics, Inc.	Helicobacter pylori bacterioferritin
US6406705B1 (en)	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US20020147143A1 (en)	1998-03-18	2002-10-10	Corixa Corporation	Compositions and methods for the therapy and diagnosis of lung cancer
PT1733735T (pt)	1998-05-22	2017-06-16	Ottawa Hospital Res Inst	Métodos e produtos para induzir imunidade mucosal
US20030235557A1 (en)	1998-09-30	2003-12-25	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
DE60036952T2 (de) *	1999-09-24	2008-08-07	Glaxosmithkline Biologicals S.A.	Influenzavirus-impfstoffzusammensetzung zur nasalen anwendung
CO5200838A1 (es) *	1999-09-24	2002-09-27	Smithkline Beecham Corp	Vacunas
EP1311288A1 (en) *	2000-01-20	2003-05-21	Ottawa Health Research Institute	Immunostimulatory nucleic acids for inducing a th2 immune response
US7585847B2 (en)	2000-02-03	2009-09-08	Coley Pharmaceutical Group, Inc.	Immunostimulatory nucleic acids for the treatment of asthma and allergy
KR100848973B1 (ko)	2000-02-23	2008-07-30	글락소스미스클라인 바이오로지칼즈 에스.에이.	종양 특이적 동물 단백질
ES2305086T3 (es)	2000-05-19	2008-11-01	Corixa Corporation	Tratamiento profilactico y terapeutico de enfermedades alergicas, autoinmunes e infecciosas con compuestos con base de monosacaridos.
EP2133100B1 (en)	2000-06-20	2011-10-05	Corixa Corporation	MTB32A Antigen of mycobacterium tuberculosis with inactivated active site and fusion proteins thereof
EP1319069B1 (en)	2000-06-28	2008-05-21	Corixa Corporation	Compositions and methods for the therapy and diagnosis of lung cancer
PL362964A1 (en) *	2000-10-02	2004-11-02	Glaxosmithkline Biologicals S.A.	Vaccine
ATE439372T1 (de)	2000-10-27	2009-08-15	Novartis Vaccines & Diagnostic	Nukleinsäuren und proteine von gruppen a und b- streptokokken
AU2002227365A1 (en)	2000-12-07	2002-06-18	Chiron Corporation	Endogenous retroviruses up-regulated in prostate cancer
ES2399386T3 (es) *	2001-04-05	2013-04-01	Novartis Vaccines And Diagnostics, Inc.	Aumento de la inmunidad de las mucosas tras sensibilización parenteral
WO2002089747A2 (en)	2001-05-09	2002-11-14	Corixa Corporation	Compositions and methods for the therapy and diagnosis of prostate cancer
TWI228420B (en) *	2001-05-30	2005-03-01	Smithkline Beecham Pharma Gmbh	Novel vaccine composition
GB0115176D0 (en)	2001-06-20	2001-08-15	Chiron Spa	Capular polysaccharide solubilisation and combination vaccines
US8481043B2 (en)	2001-06-22	2013-07-09	Cpex Pharmaceuticals, Inc.	Nasal immunization
EP1572124A4 (en)	2001-06-29	2007-11-28	Novartis Vaccines & Diagnostic	HCV E1E2 VACCINE COMPOSITIONS
GB0118249D0 (en)	2001-07-26	2001-09-19	Chiron Spa	Histidine vaccines
GB0121591D0 (en)	2001-09-06	2001-10-24	Chiron Spa	Hybrid and tandem expression of neisserial proteins
US7361352B2 (en)	2001-08-15	2008-04-22	Acambis, Inc.	Influenza immunogen and vaccine
AR045702A1 (es)	2001-10-03	2005-11-09	Chiron Corp	Composiciones de adyuvantes.
EP1581119B1 (en)	2001-12-17	2013-01-30	Corixa Corporation	Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
US8088388B2 (en)	2002-02-14	2012-01-03	United Biomedical, Inc.	Stabilized synthetic immunogen delivery system
US7501134B2 (en)	2002-02-20	2009-03-10	Novartis Vaccines And Diagnostics, Inc.	Microparticles with adsorbed polypeptide-containing molecules
US7351413B2 (en)	2002-02-21	2008-04-01	Lorantis, Limited	Stabilized HBc chimer particles as immunogens for chronic hepatitis
SE0201701D0 (sv) *	2002-06-05	2002-06-05	Gotovax Ab	Treatment of epithelial tumors and infections
ATE545651T1 (de)	2002-06-13	2012-03-15	Novartis Vaccines & Diagnostic	Vektoren zur expression von hml-2-polypeptiden
DE60226430D1 (de) *	2002-07-24	2008-06-19	Centre Nat Rech Scient	Verfahren um biologische aktive Verbindungen zu identifizieren, die anti-asthmatische und/oder anti-allergische Eigenschaften haben
GB0220194D0 (en)	2002-08-30	2002-10-09	Chiron Spa	Improved vesicles
US20040132652A1 (en) *	2002-08-30	2004-07-08	Shire Biochem Inc.	Pharmaceutical compositions
DE60335477D1 (de)	2002-10-11	2011-02-03	Novartis Vaccines & Diagnostic	Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien
ATE544466T1 (de)	2002-10-29	2012-02-15	Coley Pharm Group Inc	Verwendung von cpg oligonukleotide zur behandlung von hepatitis c virus infektion
EP2279746B1 (en)	2002-11-15	2013-10-02	Novartis Vaccines and Diagnostics S.r.l.	Surface proteins in neisseria meningitidis
GB0227346D0 (en)	2002-11-22	2002-12-31	Chiron Spa	741
EP2263687B1 (en)	2002-12-27	2015-03-25	Novartis Vaccines and Diagnostics, Inc.	Immunogenic compositions containing phospholipid
US7960522B2 (en)	2003-01-06	2011-06-14	Corixa Corporation	Certain aminoalkyl glucosaminide phosphate compounds and their use
RU2389732C2 (ru)	2003-01-06	2010-05-20	Корикса Корпорейшн	Некоторые аминоалкилглюкозаминидфосфатные производные и их применение
EP2191844B1 (en)	2003-01-30	2014-03-05	Novartis AG	Injectable vaccines against multiple meningococcal serogroups
CA2520124A1 (en)	2003-03-28	2004-10-14	Chiron Corporation	Use of benzazole compounds for immunopotentiation
GB0308198D0 (en)	2003-04-09	2003-05-14	Chiron Srl	ADP-ribosylating bacterial toxin
WO2004092360A2 (en)	2003-04-10	2004-10-28	Chiron Corporation	The severe acute respiratory syndrome coronavirus
ES2596553T3 (es)	2003-06-02	2017-01-10	Glaxosmithkline Biologicals Sa	Composiciones inmunogénicas a base de micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido
US20060035242A1 (en)	2004-08-13	2006-02-16	Michelitsch Melissa D	Prion-specific peptide reagents
GB0323103D0 (en)	2003-10-02	2003-11-05	Chiron Srl	De-acetylated saccharides
CA2885040C (en)	2003-10-02	2018-10-30	Novartis Vaccines And Diagnostics S.R.L.	Liquid vaccines for multiple meningococcal serogroups
US7399467B2 (en)	2003-12-23	2008-07-15	Arbor Vita Corporation	Antibodies for oncogenic strains of HPV and methods of their use
DE202005022108U1 (de)	2004-03-09	2013-11-12	Novartis Vaccines And Diagnostics, Inc.	Influenza-Virus-Impfstoffe
SI1740217T1 (sl)	2004-04-30	2011-10-28	Novartis Ag	Konjugirano meningokokno cepljenje
GB0409745D0 (en)	2004-04-30	2004-06-09	Chiron Srl	Compositions including unconjugated carrier proteins
GB0500787D0 (en)	2005-01-14	2005-02-23	Chiron Srl	Integration of meningococcal conjugate vaccination
GB0410866D0 (en)	2004-05-14	2004-06-16	Chiron Srl	Haemophilius influenzae
EP1766034B1 (en)	2004-05-21	2014-03-19	Novartis Vaccines and Diagnostics, Inc.	Alphavirus vectors for influenza virus vaccines
CA2837748C (en)	2004-05-25	2016-03-08	Oregon Health And Science University	Siv and hiv vaccination using rhcmv-and hcmv-based vaccine vectors
JP2008504292A (ja)	2004-06-24	2008-02-14	ノバルティスヴァクシンズアンドダイアグノスティクス，インコーポレイテッド	免疫増強用の化合物
EP1768662A2 (en)	2004-06-24	2007-04-04	Novartis Vaccines and Diagnostics, Inc.	Small molecule immunopotentiators and assays for their detection
CA2575548A1 (en)	2004-07-29	2006-07-27	John L. Telford	Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0424092D0 (en)	2004-10-29	2004-12-01	Chiron Srl	Immunogenic bacterial vesicles with outer membrane proteins
EP2682126B1 (en)	2005-01-27	2016-11-23	Children's Hospital & Research Center at Oakland	GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
GB0502095D0 (en)	2005-02-01	2005-03-09	Chiron Srl	Conjugation of streptococcal capsular saccharides
SG160329A1 (en)	2005-02-18	2010-04-29	Novartis Vaccines & Diagnostic	Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
AU2006216844B2 (en)	2005-02-18	2012-11-08	Novartis Vaccines And Diagnostics S.R.L.	Immunogens from uropathogenic escherichia coli
KR20070121814A (ko)	2005-03-31	2007-12-27	글락소스미스클라인 바이오로지칼즈 에스.에이.	클라미디아 감염에 대비한 백신
CN101237881B (zh) *	2005-08-03	2015-04-22	伊缪诺金公司	免疫偶联物剂型
JP2009511636A (ja)	2005-10-18	2009-03-19	ノバルティスヴァクシンズアンドダイアグノスティクス，インコーポレイテッド	アルファウイルスレプリコン粒子による粘膜免疫および全身免疫
EP1776963A1 (en) *	2005-10-19	2007-04-25	Gbf-Gesellschaft Für Biotechnologische Forschung Mbh	Hexosylceramides as adjuvants and their uses in pharmaceutical compositions
EP2368572B1 (en)	2005-11-04	2020-03-04	Seqirus UK Limited	Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
CA2630220C (en)	2005-11-22	2020-10-13	Doris Coit	Norovirus and sapovirus antigens
GB0524066D0 (en)	2005-11-25	2006-01-04	Chiron Srl	741 ii
NZ570106A (en)	2006-01-27	2012-04-27	Novartis Vaccines & Diagnostic	Influenza vaccines containing hemagglutinin and matrix proteins
ES2376492T3 (es)	2006-03-23	2012-03-14	Novartis Ag	Compuestos de imidazoquinoxalina como inmunomoduladores.
CA2646349A1 (en)	2006-03-24	2007-10-04	Novartis Vaccines And Diagnostics Gmbh & Co Kg	Storage of influenza vaccines without refrigeration
EP2382988A1 (en)	2006-03-31	2011-11-02	Novartis AG	Combined mucosal and parenteral immunization against HIV
WO2009030978A2 (en)	2006-06-09	2009-03-12	Novartis Ag	Conformers of bacterial adhesins
GB0614460D0 (en)	2006-07-20	2006-08-30	Novartis Ag	Vaccines
JP2010500399A (ja)	2006-08-16	2010-01-07	ノバルティスアーゲー	尿路病原性大腸菌由来の免疫原
EP1897557A1 (en) *	2006-09-07	2008-03-12	Helmholtz-Zentrum für Infektionsforschung GmbH	Use of glycolipids as adjuvants
CA3016948A1 (en)	2006-09-11	2008-03-20	Seqirus UK Limited	Making influenza virus vaccines without using eggs
PT2121011E (pt)	2006-12-06	2014-07-31	Novartis Ag	Vacinas compreendendo um antigénio a partir de quatro estirpes do vírus da gripe
GB0700562D0 (en)	2007-01-11	2007-02-21	Novartis Vaccines & Diagnostic	Modified Saccharides
MX351247B (es)	2007-04-04	2017-10-05	Infectious Disease Res Institute Star	Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
NZ582595A (en)	2007-06-27	2012-07-27	Novartis Ag	Low-additive influenza vaccines
GB0713880D0 (en)	2007-07-17	2007-08-29	Novartis Ag	Conjugate purification
GB0714963D0 (en)	2007-08-01	2007-09-12	Novartis Ag	Compositions comprising antigens
CA2695399C (en)	2007-08-02	2017-10-17	Biondvax Pharmaceuticals Ltd.	Multimeric multiepitope influenza vaccines
WO2009020553A2 (en)	2007-08-03	2009-02-12	President And Fellows Of Harvard College	Chlamydia antigens
ES2561483T3 (es)	2007-09-12	2016-02-26	Glaxosmithkline Biologicals Sa	Antígenos mutantes de GAS57 y anticuerpos de GAS57
NZ585556A (en)	2007-11-07	2012-07-27	Celldex Therapeutics Inc	Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
GB0810305D0 (en)	2008-06-05	2008-07-09	Novartis Ag	Influenza vaccination
AU2008331800A1 (en)	2007-12-03	2009-06-11	President And Fellows Of Harvard College	Chlamydia antigens
EP2244695A1 (en)	2007-12-07	2010-11-03	Novartis AG	Compositions for inducing immune responses
GB0818453D0 (en)	2008-10-08	2008-11-12	Novartis Ag	Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
PL2235046T3 (pl)	2007-12-21	2012-12-31	Novartis Ag	Zmutowane formy streptolizyny O
BRPI0907843A2 (pt)	2008-02-21	2015-08-04	Novartis Ag	Polipeptídeos de fhbp menigocócicos
ES2557282T3 (es)	2008-03-10	2016-01-25	Children's Hospital & Research Center At Oakland	Proteínas quiméricas de unión al factor H (fHBP) que contienen un dominio B heterólogo, y métodos de uso
JP2012510289A (ja)	2008-12-03	2012-05-10	プロティアワクチンテクノロジーズリミテッド	グルタミルｔＲＮＡ合成酵素（ＧｔＳ）フラグメント
CA2744754A1 (en)	2008-12-09	2010-06-17	Pfizer Vaccines Llc	Ige ch3 peptide vaccine
CA2749367A1 (en)	2009-01-12	2010-07-15	Novartis Ag	Cna_b domain antigens in vaccines against gram positive bacteria
JP2012519482A (ja)	2009-03-06	2012-08-30	ノバルティスアーゲー	クラミジア抗原
MX2011010735A (es)	2009-04-14	2012-01-25	Novartis Ag	Composiciones para inmunizacion contra staphylococcus aureus.
CA2757620C (en)	2009-04-30	2016-04-26	Coley Pharmaceutical Group, Inc.	Pneumococcal vaccine and uses thereof
CA2765364C (en)	2009-06-15	2015-05-26	National University Of Singapore	Influenza vaccine, composition, and methods of use
US10988511B2 (en)	2009-07-07	2021-04-27	Glaxosmithkline Biologicals Sa	Conserved Escherichia bacterial IG-like domain (group 1) protein (ORF405) immunogens
EP3178490B1 (en)	2009-07-15	2022-04-20	GlaxoSmithKline Biologicals S.A.	Rsv f protein compositions and methods for making same
US8871214B2 (en)	2009-07-16	2014-10-28	Novartis Ag	Detoxified Escherichia coli immunogens
NZ618391A (en)	2009-07-30	2015-07-31	Pfizer Vaccines Llc	Antigenic tau peptides and uses thereof
CN102596240B (zh)	2009-08-27	2015-02-04	诺华股份有限公司	包括脑膜炎球菌fHBP序列的杂交多肽
CN104548089B (zh)	2009-09-03	2017-09-26	辉瑞疫苗有限责任公司	Pcsk9疫苗
JP2013506651A (ja)	2009-09-30	2013-02-28	ノバルティスアーゲー	Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ．ａｕｒｅｕｓ５型および８型莢膜多糖の結合体
GB0918392D0 (en)	2009-10-20	2009-12-02	Novartis Ag	Diagnostic and therapeutic methods
BR112012010531A2 (pt)	2009-10-27	2019-09-24	Novartis Ag	"polipeptídeos de modificação meningocócica fhbp"
WO2011056899A2 (en)	2009-11-03	2011-05-12	Ligocyte Pharmaceuticals, Inc.	Chimeric rsv-f polypeptide and lentivirus or alpha-retrovirus gag-based vlps
GB0919690D0 (en)	2009-11-10	2009-12-23	Guy S And St Thomas S Nhs Foun	compositions for immunising against staphylococcus aureus
WO2011067758A2 (en)	2009-12-02	2011-06-09	Protea Vaccine Technologies Ltd.	Immunogenic fragments and multimers from streptococcus pneumoniae proteins
NZ600978A (en)	2009-12-22	2014-08-29	Celldex Therapeutics Inc	Vaccine compositions
JP5781542B2 (ja)	2009-12-30	2015-09-24	ノバルティスアーゲー	Ｅ．ｃｏｌｉキャリアタンパク質に結合体化した多糖免疫原
GB201003333D0 (en)	2010-02-26	2010-04-14	Novartis Ag	Immunogenic proteins and compositions
EP4036104B1 (en)	2010-03-30	2024-02-21	Children's Hospital & Research Center at Oakland	Factor h binding proteins (fhbp) with altered properties and methods of use thereof
GB201005625D0 (en)	2010-04-01	2010-05-19	Novartis Ag	Immunogenic proteins and compositions
EP2556151A1 (en)	2010-04-07	2013-02-13	Novartis AG	Method for generating a parvovirus b19 virus-like particle
CN103154034B (zh)	2010-04-13	2016-06-08	塞尔德克斯医疗公司	结合人cd27的抗体及其用途
WO2011130379A1 (en)	2010-04-13	2011-10-20	Novartis Ag	Benzonapthyridine compositions and uses thereof
WO2011149564A1 (en)	2010-05-28	2011-12-01	Tetris Online, Inc.	Interactive hybrid asynchronous computer game infrastructure
EP2576613A1 (en)	2010-06-07	2013-04-10	Pfizer Inc.	Her-2 peptides and vaccines
CA2800774A1 (en)	2010-06-07	2011-12-15	Pfizer Vaccines Llc	Ige ch3 peptide vaccine
GB201009861D0 (en)	2010-06-11	2010-07-21	Novartis Ag	OMV vaccines
US20130171185A1 (en)	2010-07-06	2013-07-04	Ethan Settembre	Norovirus derived immunogenic compositions and methods
US9192661B2 (en)	2010-07-06	2015-11-24	Novartis Ag	Delivery of self-replicating RNA using biodegradable polymer particles
GB201101665D0 (en)	2011-01-31	2011-03-16	Novartis Ag	Immunogenic compositions
US20130345079A1 (en)	2010-10-27	2013-12-26	Infectious Disease Research Institute	Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
BR112013011420A2 (pt)	2010-11-08	2016-08-02	Infectious Disease Res Inst	vacinas compreendendo poliptídeos de nucleosídeo hidrolase não específica e esterol 24-c-metil-transferase (smt) para o tratamento e o diagnóstico de leishmaníase
WO2012072769A1 (en)	2010-12-01	2012-06-07	Novartis Ag	Pneumococcal rrgb epitopes and clade combinations
EP3023106B1 (en) *	2010-12-14	2019-07-31	GlaxoSmithKline Biologicals S.A.	Mycobacterium antigenic composition
US20130315959A1 (en)	2010-12-24	2013-11-28	Novartis Ag	Compounds
DK2667892T3 (da)	2011-01-26	2019-05-13	Glaxosmithkline Biologicals Sa	RSV-vaccineringsprogram
AU2011360572B2 (en)	2011-02-22	2017-03-02	Biondvax Pharmaceuticals Ltd.	Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
US20140004142A1 (en)	2011-03-02	2014-01-02	Pfizer Inc.	Pcsk9 vaccine
GB201106357D0 (en)	2011-04-14	2011-06-01	Pessi Antonello	Composition and uses thereof
SI3275892T1 (sl)	2011-05-13	2020-06-30	Glaxosmithkline Biologicals S.A.	Prefuzijski RSV F antigeni
EP2723365A1 (en)	2011-06-21	2014-04-30	Oncofactor Corporation	Compositions and methods for the therapy and diagnosis of cancer
EP3332802A1 (en)	2011-07-06	2018-06-13	GlaxoSmithKline Biologicals SA	Immunogenic combination compositions and uses thereof
JP2014520807A (ja)	2011-07-06	2014-08-25	ノバルティスアーゲー	免疫原性組成物およびその使用
ES2687129T3 (es)	2011-07-25	2018-10-23	Glaxosmithkline Biologicals Sa	Composiciones y métodos para evaluar la inmunogenicidad funcional de vacunas contra parvovirus
GB201114923D0 (en)	2011-08-30	2011-10-12	Novartis Ag	Immunogenic proteins and compositions
CN103930436A (zh)	2011-09-14	2014-07-16	诺华股份有限公司	大肠杆菌疫苗组合
ES2704069T3 (es)	2011-12-08	2019-03-14	Glaxosmithkline Biologicals Sa	Vacuna basada en toxinas de Clostridium difficile
WO2013108272A2 (en)	2012-01-20	2013-07-25	International Centre For Genetic Engineering And Biotechnology	Blood stage malaria vaccine
RU2014138418A (ru)	2012-02-24	2016-04-10	Новартис Аг	Белки пилей и композиции
WO2013150518A1 (en)	2012-04-01	2013-10-10	Rappaport Family Institute For Research In The Medical Sciences	Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
CN108671228A (zh)	2012-04-26	2018-10-19	诺华股份有限公司	抗原和抗原组合
US10279026B2 (en)	2012-04-26	2019-05-07	Glaxosmithkline Biologicals Sa	Antigens and antigen combinations
EP2659906A1 (en)	2012-05-01	2013-11-06	Affiris AG	Compositions
EP2659908A1 (en)	2012-05-01	2013-11-06	Affiris AG	Compositions
EP2659907A1 (en)	2012-05-01	2013-11-06	Affiris AG	Compositions
CN105457021A (zh)	2012-05-04	2016-04-06	辉瑞公司	前列腺相关抗原及基于疫苗的免疫治疗疗法
SG11201407440WA (en)	2012-05-22	2014-12-30	Novartis Ag	Meningococcus serogroup x conjugate
EP2869842A1 (en)	2012-07-06	2015-05-13	Novartis AG	Immunogenic compositions and uses thereof
PT2879701T (pt)	2012-08-03	2024-02-12	Access To Advanced Health Inst	Composições e métodos para o tratamento de uma infeção ativa por mycobacterium tuberculosis
CN105307684A (zh)	2012-10-02	2016-02-03	葛兰素史密丝克莱恩生物有限公司	非直链糖缀合物
WO2014053612A1 (en)	2012-10-03	2014-04-10	Novartis Ag	Immunogenic composition
SG11201504258RA (en)	2012-11-30	2015-07-30	Glaxosmithkline Biolog Sa	Pseudomonas antigens and antigen combinations
BR112015024860B1 (pt)	2013-03-28	2023-11-07	Access To Advanced Health Institute	Polipeptídeo de fusão, polinucleotídeo isolado, composição compreendendo dito polipeptídeo, uso da dita composição para estimular uma resposta imune contra leishmania e método in vitro e kit de diagnóstico para detectar infecção por leishmania em uma amostra biológica
US20210145963A9 (en)	2013-05-15	2021-05-20	The Governors Of The University Of Alberta	E1e2 hcv vaccines and methods of use
PT3096785T (pt)	2014-01-21	2020-10-13	Pfizer	Composições imunogénicas que compreendem antigénios de sacáridos capsulares conjugados e utilizações das mesmas
US11160855B2 (en)	2014-01-21	2021-11-02	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US10279019B2 (en)	2014-02-11	2019-05-07	Stc.Unm	PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same
JP6796057B2 (ja)	2014-07-23	2020-12-02	チルドレンズホスピタルアンドリサーチセンターアットオークランド	Ｈ因子結合タンパク質変異体及びその使用方法
AU2015252119A1 (en)	2014-11-07	2016-05-26	Takeda Vaccines, Inc.	Hand, foot, and mouth vaccines and methods of manufacture and use thereof
MA40920A (fr)	2014-11-07	2017-09-12	Takeda Vaccines Inc	Vaccins de la main, du pied et de la bouche, et procédés de fabrication et d'utilisation de ceux-ci
DK3233912T3 (da)	2014-12-19	2021-08-02	Regenesance B V	Antistoffer, der binder human c6, og anvendelser deraf
MX395525B (es)	2015-01-15	2025-03-25	Pfizer	Composiciones inmunogenicas para usar en vacunas neumococicas.
EP3268037B1 (en)	2015-03-09	2022-08-31	Celldex Therapeutics, Inc.	Cd27 agonists
CA2986961C (en)	2015-05-26	2023-07-25	Ohio State Innovation Foundation	Nanoparticle based vaccine strategy against swine influenza virus
WO2016193405A1 (en)	2015-06-03	2016-12-08	Affiris Ag	Il-23-p19 vaccines
AU2016289497A1 (en)	2015-07-07	2017-12-07	Affiris Ag	Vaccines for the treatment and prevention of IgE mediated diseases
MY192183A (en)	2015-07-21	2022-08-05	Pfizer	Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
AU2016311387B2 (en)	2015-08-25	2023-02-23	Babita Agrawal	Immunomodulatory compositions and methods of use thereof
CN108290960B (zh)	2015-10-08	2023-06-09	艾伯塔大学理事会	丙型肝炎病毒e1/e2异二聚体及其生产方法
CA3005524C (en)	2015-11-20	2023-10-10	Pfizer Inc.	Immunogenic compositions for use in pneumococcal vaccines
EP3733201A1 (en)	2016-01-19	2020-11-04	Pfizer Inc	Cancer vaccines
WO2017184619A2 (en)	2016-04-18	2017-10-26	Celldex Therapeutics, Inc.	Agonistic antibodies that bind human cd40 and uses thereof
WO2017205225A2 (en)	2016-05-21	2017-11-30	Infectious Disease Research Institute	Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections
WO2018053294A1 (en)	2016-09-16	2018-03-22	Infectious Disease Research Institute	Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
HRP20220573T1 (hr)	2017-01-20	2022-06-10	Pfizer Inc.	Imunogeni pripravci, namijenjeni upotrebi u pneumokoknim cjepivima
WO2019035963A1 (en)	2017-08-16	2019-02-21	Ohio State Innovation Foundation	NANOPARTICLE COMPOSITIONS FOR VACCINES AGAINST SALMONELLA
CN111615397B (zh)	2017-11-03	2024-09-13	武田疫苗股份有限公司	寨卡疫苗和免疫原性组合物及其使用方法
WO2019173438A1 (en)	2018-03-06	2019-09-12	Stc. Unm	Compositions and methods for reducing serum triglycerides
SG11202010011RA (en)	2018-04-17	2020-11-27	Celldex Therapeutics Inc	Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
US11260119B2 (en)	2018-08-24	2022-03-01	Pfizer Inc.	Escherichia coli compositions and methods thereof
EP3851120A4 (en)	2018-09-11	2022-04-27	Shanghai Public Health Clinical Center	Immunogen for broad-spectrum influenza vaccine and application thereof
CA3119857A1 (en)	2018-11-16	2020-05-22	Versitech Limited	Live attenuated influenza b virus compositions methods of making and using thereof
WO2020123444A1 (en)	2018-12-11	2020-06-18	Celldex Therapeutics, Inc.	Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy
CA3120922A1 (en)	2018-12-12	2020-06-18	Pfizer Inc.	Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
JP7239509B6 (ja)	2019-02-22	2023-03-28	ファイザー・インク	細菌多糖類を精製するための方法
EP3952906A1 (en)	2019-04-10	2022-02-16	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
KR20220092572A (ko)	2019-11-01	2022-07-01	화이자 인코포레이티드	에스케리키아 콜라이 조성물 및 그 방법
NL2030835B1 (en)	2020-01-24	2022-12-29	Aim Immunotech Inc	Methods, compositions, and vaccinces for treating a virus infection
WO2021165847A1 (en)	2020-02-21	2021-08-26	Pfizer Inc.	Purification of saccharides
CN115605498A (zh)	2020-02-23	2023-01-13	辉瑞公司（Us）	大肠杆菌组合物及其方法
CN115175924A (zh)	2020-02-26	2022-10-11	港大科桥有限公司	基于pd-1的针对冠状病毒感染的疫苗
WO2022020810A1 (en) *	2020-07-24	2022-01-27	The Board Of Trustees Of The Leland Stanford Junior University	A three component vaccine for covid-19
US12138302B2 (en)	2020-10-27	2024-11-12	Pfizer Inc.	Escherichia coli compositions and methods thereof
TW202227467A (zh)	2020-10-27	2022-07-16	美商輝瑞大藥廠	大腸桿菌組合物及其方法
KR20230097160A (ko)	2020-11-04	2023-06-30	화이자 인코포레이티드	폐렴구균 백신에 사용하기 위한 면역원성 조성물
JP7804673B2 (ja)	2020-11-10	2026-01-22	ファイザー・インク	コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
US12357681B2 (en)	2020-12-23	2025-07-15	Pfizer Inc.	E. coli FimH mutants and uses thereof
WO2022147373A1 (en)	2020-12-31	2022-07-07	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
CA3211240A1 (en)	2021-02-19	2022-08-25	Sanofi Pasteur Inc.	Meningococcal b recombinant vaccine
MX2023011788A (es)	2021-04-09	2023-10-11	Celldex Therapeutics Inc	Anticuerpos contra ilt4, anticuerpo biespecifico anti-ilt4/pd-l1 y usos de los mismos.
US20240226280A1 (en)	2021-05-04	2024-07-11	King Abdullah University Of Science And Technology	Immuogenic compositions of mutant sars-cov-2 n protein and gene and methods of use thereof
US20220387613A1 (en)	2021-05-28	2022-12-08	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA3221075A1 (en)	2021-05-28	2022-12-01	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023079529A1 (en)	2021-11-05	2023-05-11	King Abdullah University Of Science And Technology	Re-focusing protein booster immunization compositions and methods of use thereof
WO2023079528A1 (en)	2021-11-05	2023-05-11	King Abdullah University Of Science And Technology	Compositions suitable for use in a method for eliciting cross-protective immunity against coronaviruses
WO2023077521A1 (en)	2021-11-08	2023-05-11	Celldex Therapeutics, Inc	Anti-ilt4 and anti-pd-1 bispecific constructs
JP2024541094A (ja)	2021-11-18	2024-11-06	マトリバックス，インコーポレイティド	免疫原性融合タンパク質組成物及びその使用の方法
AU2023207315A1 (en)	2022-01-13	2024-06-27	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR102420201B1 (ko) *	2022-01-17	2022-07-13	주식회사 유이케미칼	인지질 외피 보유 바이러스 사멸기능을 가지는 친환경 방역 조성물
WO2023161817A1 (en)	2022-02-25	2023-08-31	Pfizer Inc.	Methods for incorporating azido groups in bacterial capsular polysaccharides
CN119317445A (zh)	2022-05-11	2025-01-14	辉瑞公司	用于生产含有防腐剂的疫苗制剂的方法
JP2025525623A (ja)	2022-07-22	2025-08-05	アンスティチュナシヨナルデュラサンテエトデュラレシェルシェメディカレ	慢性閉塞性肺疾患の治療のためのボルデテラ（ｂｏｒｄｅｔｅｌｌａ）菌株の使用
WO2024110827A1 (en)	2022-11-21	2024-05-30	Pfizer Inc.	Methods for preparing conjugated capsular saccharide antigens and uses thereof
AU2023385908A1 (en)	2022-11-22	2025-05-15	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20250113501A (ko)	2022-12-01	2025-07-25	화이자 인코포레이티드	폐렴구균 접합체 백신 제형
WO2024130009A1 (en)	2022-12-14	2024-06-20	Yale University	Compositions and methods of use thereof for the treatment of virally driven cancers
EP4661911A1 (en)	2023-02-10	2025-12-17	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN121219315A (zh)	2023-03-03	2025-12-26	塞德斯医疗公司	抗干细胞因子(scf)和抗胸腺基质淋巴细胞生成素(tslp)抗体及双特异性构建体
AU2024246082A1 (en)	2023-03-30	2025-10-16	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN121057590A (zh)	2023-04-14	2025-12-02	辉瑞公司	包含缀合荚膜糖抗原的免疫原性组合物及其用途
WO2024224266A1 (en)	2023-04-24	2024-10-31	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP4483898A1 (en) *	2023-06-28	2025-01-01	Advagene Biopharma Co., Ltd.	Intranasal vaccine composition and method for boosting using the same
WO2025133971A1 (en)	2023-12-23	2025-06-26	Pfizer Inc.	Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025186705A2 (en)	2024-03-06	2025-09-12	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2025191415A1 (en)	2024-03-11	2025-09-18	Pfizer Inc.	Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
WO2025219904A1 (en)	2024-04-19	2025-10-23	Pfizer Inc.	Improved methods for producing glycoconjugates by reductive amination in aprotic solvent

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3919411A (en) *	1972-01-31	1975-11-11	Bayvet Corp	Injectable adjuvant and compositions including such adjuvant
JPH05201877A (ja) *	1992-01-30	1993-08-10	Kanebo Ltd	アジュバント組成物
WO1994017827A1 (en) *	1993-02-15	1994-08-18	Lyfjathroun H.F.	A pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via a mucosal membrane

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3867635D1 (de) *	1987-03-13	1992-02-20	Micro Vesicular Systems	Lipidversikel aus grenzflaechenaktiven stoffen und sterolen.
GB9207731D0 (en) *	1992-04-07	1992-05-27	Proteus Molecular Design	Improvements in or relating to vaccines
JPH06172216A (ja) *	1992-12-04	1994-06-21	Norin Suisanshiyou Kachiku Eisei Shikenjo	乳液状オイルアジュバント
GB9320597D0 (en) *	1993-10-06	1993-11-24	Proteus Molecular Design	Improvements in and realting to vaccines
CA2194761C (en) *	1994-07-15	2006-12-19	Arthur M. Krieg	Immunomodulatory oligonucleotides

1999
- 1999-03-29 AU AU34197/99A patent/AU746163B2/en not_active Ceased
- 1999-03-29 IL IL13800099A patent/IL138000A0/xx unknown
- 1999-03-29 PL PL99354714A patent/PL354714A1/xx unknown
- 1999-03-29 TR TR2000/02930T patent/TR200002930T2/xx unknown
- 1999-03-29 CA CA002325939A patent/CA2325939A1/en not_active Abandoned
- 1999-03-29 NZ NZ506603A patent/NZ506603A/xx unknown
- 1999-03-29 BR BR9909915-2A patent/BR9909915A/pt not_active IP Right Cessation
- 1999-03-29 WO PCT/EP1999/002278 patent/WO1999052549A1/en not_active Ceased
- 1999-03-29 CN CN99804894A patent/CN1296416A/zh active Pending
- 1999-03-29 JP JP2000543159A patent/JP2002511423A/ja active Pending
- 1999-03-29 EP EP99915735A patent/EP1069910A1/en not_active Withdrawn
- 1999-03-29 HU HU0101619A patent/HUP0101619A3/hu unknown
- 1999-03-29 KR KR1020007011240A patent/KR20010042573A/ko not_active Withdrawn
- 1999-04-07 AR ARP990101567A patent/AR019026A1/es unknown
2000
- 2000-10-06 NO NO20005051A patent/NO20005051L/no not_active Application Discontinuation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3919411A (en) *	1972-01-31	1975-11-11	Bayvet Corp	Injectable adjuvant and compositions including such adjuvant
JPH05201877A (ja) *	1992-01-30	1993-08-10	Kanebo Ltd	アジュバント組成物
WO1994017827A1 (en) *	1993-02-15	1994-08-18	Lyfjathroun H.F.	A pharmaceutical preparation for topical administration of antigens and/or vaccines to mammals via a mucosal membrane

Also Published As

Publication number	Publication date
NO20005051L (no)	2000-11-21
KR20010042573A (ko)	2001-05-25
EP1069910A1 (en)	2001-01-24
CN1296416A (zh)	2001-05-23
PL354714A1 (en)	2004-02-09
IL138000A0 (en)	2001-10-31
HUP0101619A3 (en)	2003-11-28
JP2002511423A (ja)	2002-04-16
BR9909915A (pt)	2000-12-26
AR019026A1 (es)	2001-12-26
WO1999052549A1 (en)	1999-10-21
HUP0101619A2 (hu)	2001-08-28
TR200002930T2 (tr)	2000-12-21
NZ506603A (en)	2002-10-25
NO20005051D0 (no)	2000-10-06
AU3419799A (en)	1999-11-01
CA2325939A1 (en)	1999-10-21

Publication	Publication Date	Title
AU746163B2 (en)	2002-04-18	Adjuvant compositions
AU766635B2 (en)	2003-10-23	Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
AU765824B2 (en)	2003-10-02	Vaccines
US6558670B1 (en)	2003-05-06	Vaccine adjuvants
AU764969B2 (en)	2003-09-04	Vaccines
JP5307859B2 (ja)	2013-10-02	ワクチン
CZ20003732A3 (cs)	2001-04-11	Pomocný prostředek
MXPA00009887A (es)	2001-07-09	Composicion adyuvante
ZA200202268B (en)	2003-02-03	Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one non-ionic surfactant.
ZA200202270B (en)	2003-02-12	Use of combination of polyxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines.
HK1118481A (en)	2009-02-13	Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
HK1151231A (en)	2012-01-27	Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
HK1079088A (en)	2006-03-31	Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide

Legal Events

Date	Code	Title	Description
2002-08-15	FGA	Letters patent sealed or granted (standard patent)